Karius' new financing will support clinical trials and commercialization of its NGS-based infectious disease test, and will help scale up laboratory capacity.
Stakeholders increasingly highlight the need for better, more standardized tools to validate and compare liquid biopsy tests, and commercial firms have responded.
The Pro-Seq technology links molecules prior to sequencing to enable detection of low-frequency variants, and could be complementary to Boreal's OnTarget technology.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
Diagnostics firm BioHisto Maroc will market and distribute the firm's tissue-based and liquid biopsy sequencing services to oncologists and their patients.
Novogene will validate Trovagene's proprietary urine collection and nucleic acid preservation device, NextCollect, and develop tests for the Chinese market.
The company has not published on its technology, but claims proprietary materials and methods allow it to detect targets in unprocessed biological samples with sub-femtomolar sensitivity.
